Denosumab (Prolia)
for Osteoporosis
Denosumab is a biologic injection given 6-monthly for osteoporosis — highly effective for reducing fracture risk, particularly in post-menopausal women and those who cannot tolerate bisphosphonates.
How it works
Monoclonal antibody against RANK ligand (RANKL), inhibiting osteoclast formation and activity. Provides potent bone resorption inhibition comparable to bisphosphonates but with a different mechanism.
What to watch for
Prescription and specialist managed. Critical: must not be stopped abruptly — discontinuation can cause rapid bone loss and rebound vertebral fractures. Transition to bisphosphonate is needed on stopping. Infection risk.
Community experience
Other remedies for Osteoporosis
See all 10 remedies →WikiRemedy surfaces community experience, not medical advice. Always consult a qualified health professional.